Immunopathology caused by impaired CD8
CD8+ T cells
T-cell exhaustion
chronic viral hepatitis
immunopathology
primary hemophagocytic lymphohistiocytosis
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
16
11
2021
received:
16
11
2021
accepted:
24
01
2022
pubmed:
1
2
2022
medline:
9
9
2022
entrez:
31
1
2022
Statut:
ppublish
Résumé
Recent findings indicate that many immunopathologies are at their roots a consequence of impaired immune responses ("too little" immunity) and not the result of primarily exaggerated immune responses ("too much" immunity). We have summarized this conceptional view as "IMPATH paradox." In this review, we will focus on impaired immune reactions in the context of CD8
Identifiants
pubmed: 35099807
doi: 10.1002/eji.202149528
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1390-1395Informations de copyright
© 2022 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Références
Halle, S., Halle, O. and Forster, R., Mechanisms and dynamics of T cell-mediated cytotoxicity in vivo. Trends Immunol. 2017. 38: 432-443.
Zhang, N. and Bevan, M. J., CD8(+) T cells: foot soldiers of the immune system. Immunity 2011. 35: 161-168.
Kagi, D., Vignaux, F., Ledermann, B., Burki, K., Depraetere, V., Nagata, S., Hengartner, H. et al., Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994. 265: 528-530.
Dustin, M. L. and Long, E. O., Cytotoxic immunological synapses. Immunol. Rev. 2010. 235: 24-34.
Cole, G. A., Nathanson, N. and Prendergast, R. A., Requirement for theta-bearing cells in lymphocytic choriomeningitis virus-induced central nervous system disease. Nature 1972. 238: 335-337.
Doherty, P. C. and Zinkernagel, R. M., T-cell-mediated immunopathology in viral infections. Transplant. Rev. 1974. 19: 89-120.
Kagi, D., Ledermann, B., Burki, K., Zinkernagel, R. M. and Hengartner, H., Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu. Rev. Immunol. 1996. 14: 207-232.
Henter, J. I., Elinder, G., Soder, O., Hansson, M., Andersson, B. and Andersson, U., Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991. 78: 2918-2922.
Janka, G. E. and Lehmberg, K., Hemophagocytic syndromes-an update. Blood Rev. 2014. 28: 135-142.
Sepulveda, F. E. and de Saint Basile, G., Hemophagocytic syndrome: primary forms and predisposing conditions. Curr. Opin. Immunol. 2017. 49: 20-26.
Heeg, M., Ammann, S., Klemann, C., Panning, M., Falcone, V., Hengel, H., Lehmberg, K., et al., Is an infectious trigger always required for primary hemophagocytic lymphohistiocytosis? Lessons from in utero and neonatal disease. Pediatr. Blood. Cancer 2018. 65: e27344.
Ehl, S., Astigarraga, I., von Bahr Greenwood, T., Hines, M., Horne, A., Ishii, E., Janka, G., et al., Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH steering committee of the Histiocyte Society. J. Allergy Clin. Immunol. Pract. 2018. 6: 1508-1517.
Henter, J. I., Horne, A., Arico, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., Ladisch, S., et al., HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 2007. 48: 124-131.
Keenan, C., Nichols, K. E. and Albeituni, S., Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front. Immunol. 2021. 12: 614704.
Locatelli, F., Jordan, M. B., Allen, C., Cesaro, S., Rizzari, C., Rao, A., Degar, B., et al., Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N. Engl. J. Med. 2020. 382: 1811-1822.
Wegehaupt, O., Wustrau, K., Lehmberg, K. and Ehl, S., Cell versus cytokine-directed therapies for hemophagocytic lymphohistiocytosis (HLH) in inborn errors of immunity. Front. Immunol. 2020. 11: 808.
de Saint Basile, G., Menasche, G. and Fischer, A., Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat. Rev. Immunol. 2010. 10: 568-579.
Pachlopnik Schmid, J., Cote, M., Menager, M. M., Burgess, A., Nehme, N., Menasche, G., Fischer, A. et al., Inherited defects in lymphocyte cytotoxic activity. Immunol. Rev. 2010. 235: 10-23.
Crozat, K., Hoebe, K., Ugolini, S., Hong, N. A., Janssen, E., Rutschmann, S., Mudd, S., et al., Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J. Exp. Med. 2007. 204: 853-863.
Gather, R., Aichele, P., Goos, N., Rohr, J., Pircher, H., Kogl, T., Zeiser, R., et al., Trigger-dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis. Eur. J. Immunol. 2020. 50: 1770-1782.
Jordan, M. B., Hildeman, D., Kappler, J. and Marrack, P., An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004. 104: 735-743.
Kogl, T., Muller, J., Jessen, B., Schmitt-Graeff, A., Janka, G., Ehl, S., zur Stadt, U. et al., Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease. Blood 2013. 121: 604-613.
Sepulveda, F. E., Debeurme, F., Menasche, G., Kurowska, M., Cote, M., Pachlopnik Schmid, J., Fischer, A. et al., Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11. Blood 2013. 121: 595-603.
Jessen, B., Kogl, T., Sepulveda, F. E., de Saint Basile, G., Aichele, P. and Ehl, S., Graded defects in cytotoxicity determine severity of hemophagocytic lymphohistiocytosis in humans and mice. Front. Immunol. 2013. 4: 448.
Kagi, D., Ledermann, B., Burki, K., Seiler, P., Odermatt, B., Olsen, K. J., Podack, E. R. et al., Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994. 369: 31-37.
Terrell, C. E. and Jordan, M. B., Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells. Blood 2013. 121: 5184-5191.
Binder, D., van den Broek, M. F., Kagi, D., Bluethmann, H., Fehr, J., Hengartner, H. and Zinkernagel, R. M., Aplastic anemia rescued by exhaustion of cytokine-secreting CD8+ T cells in persistent infection with lymphocytic choriomeningitis virus. J. Exp. Med. 1998. 187: 1903-1920.
Spearman, C. W., Dusheiko, G. M., Hellard, M. and Sonderup, M., Hepatitis C. Lancet 2019. 394: 1451-1466.
Gehring, A. J. and Protzer, U., Targeting innate and adaptive immune responses to cure chronic HBV infection. Gastroenterology 2019. 156: 325-337.
Lang-Meli, J., Neumann-Haefelin, C. and Thimme, R., Immunotherapy and therapeutic vaccines for chronic HBV infection. Curr. Opin. Virol. 2021. 51: 149-157.
Wieland, S. F. and Chisari, F. V., Stealth and cunning: hepatitis B and hepatitis C viruses. J. Virol. 2005. 79: 9369-9380.
Rehermann, B. and Thimme, R., Insights from antiviral therapy into immune responses to hepatitis b and c virus infection. Gastroenterology 2019. 156: 369-383.
Zehn, D., Utzschneider, D. T. and Thimme, R., Immune-surveillance through exhausted effector T-cells. Curr. Opin. Virol. 2016. 16: 49-54.
Nitschke, K., Luxenburger, H., Kiraithe, M. M., Thimme, R. and Neumann-Haefelin, C., CD8+ T-cell responses in hepatitis B and C: the (HLA-) A, B, and C of hepatitis B and C. Dig. Dis. 2016. 34: 396-409.
Salimi Alizei, E., Hofmann, M., Thimme, R. and Neumann-Haefelin, C., Mutational escape from cellular immunity in viral hepatitis: variations on a theme. Curr. Opin. Virol. 2021. 50: 110-118.
Blank, C. U., Haining, W. N., Held, W., Hogan, P. G., Kallies, A., Lugli, E., Lynn, R. C., et al., Defining ‘T cell exhaustion’. Nat. Rev. Immunol. 2019. 19: 665-674.
Bengsch, B., Ohtani, T., Herati, R. S., Bovenschen, N., Chang, K. M. and Wherry, E. J., Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns. J. Immunol. Methods 2018. 453: 3-10.
Abdel-Hakeem, M. S., Manne, S., Beltra, J. C., Stelekati, E., Chen, Z., Nzingha, K., Ali, M. A., et al., Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation. Nat. Immunol. 2021. 22: 1008-1019.
Hensel, N., Gu, Z., Sagar, Wieland, D., Jechow, K., Kemming, J., Llewellyn-Lacey, S. et al., Memory-like HCV-specific CD8(+) T cells retain a molecular scar after cure of chronic HCV infection. Nat. Immunol. 2021. 22: 229-239.
Tonnerre, P., Wolski, D., Subudhi, S., Aljabban, J., Hoogeveen, R. C., Damasio, M., Drescher, H. K. et al., Differentiation of exhausted CD8(+) T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory. Nat. Immunol. 2021. 22: 1030-1041.
Yates, K. B., Tonnerre, P., Martin, G. E., Gerdemann, U., Al Abosy, R., Comstock, D. E., Weiss, S. A. et al., Epigenetic scars of CD8(+) T cell exhaustion persist after cure of chronic infection in humans. Nat. Immunol. 2021. 22: 1020-1029.
Wieland, D., Kemming, J., Schuch, A., Emmerich, F., Knolle, P., Neumann-Haefelin, C., Held, W. et al., TCF1(+) hepatitis C virus-specific CD8(+) T cells are maintained after cessation of chronic antigen stimulation. Nat. Commun. 2017. 8: 15050.
Alfei, F., Kanev, K., Hofmann, M., Wu, M., Ghoneim, H. E., Roelli, P., Utzschneider, D. T. et al., TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 2019. 571: 265-269.
Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T. et al., TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature 2019. 571: 211-218.
Scott, A. C., Dundar, F., Zumbo, P., Chandran, S. S., Klebanoff, C. A., Shakiba, M., Trivedi, P. et al., TOX is a critical regulator of tumour-specific T cell differentiation. Nature 2019. 571: 270-274.
Heim, K., Binder, B., Sagar, Wieland, D., Hensel, N., Llewellyn-Lacey, S., Gostick, E. et al., TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection. Gut 2020.
Hoogeveen, R. C., Robidoux, M. P., Schwarz, T., Heydmann, L., Cheney, J. A., Kvistad, D., Aneja, J. et al., Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection. Gut 2019. 68: 893-904.
Schuch, A., Salimi Alizei, E., Heim, K., Wieland, D., Kiraithe, M. M., Kemming, J., Llewellyn-Lacey, S. et al., Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. Gut 2019. 68: 905-915.
Ghosh, S., Carmo, M., Calero-Garcia, M., Ricciardelli, I., Bustamante Ogando, J. C., Blundell, M. P., Schambach, A. et al., T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations. J. Allergy Clin. Immunol. 2018. 142: 904-913.
Terrell, C. E. and Jordan, M. B., Mixed hematopoietic or T-cell chimerism above a minimal threshold restores perforin-dependent immune regulation in perforin-deficient mice. Blood 2013. 122: 2618-2621.